We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action.
- Authors
Surmiak, Ewa; Magiera-Mularz, Katarzyna; Musielak, Bogdan; Muszak, Damian; Kocik-Krol, Justyna; Kitel, Radoslaw; Plewka, Jacek; Holak, Tad A.; Skalniak, Lukasz
- Abstract
Targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) interaction has become an established strategy for cancer immunotherapy. Although hundreds of small-molecule, peptide, and peptidomimetic inhibitors have been proposed in recent years, only a limited number of drug candidates show good PD-1/PD-L1 blocking activity in cell-based assays. In this article, we compare representative molecules from different classes in terms of their PD-1/PD-L1 dissociation capacity measured by HTRF and in vitro bioactivity determined by the immune checkpoint blockade (ICB) co-culture assay. We point to recent discoveries that underscore important differences in the mechanisms of action of these molecules and also indicate one principal feature that needs to be considered, which is the eventual human PD-L1 specificity.
- Subjects
IMMUNE checkpoint proteins; PROGRAMMED death-ligand 1; IMMUNOTHERAPY; CELL death; PROGRAMMED cell death 1 receptors
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 21, p11797
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms222111797